icon-    folder.gif   Conference Reports for NATAP  
 
  Presented at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL)
Taipei, Taiwan
February 16-19, 2012
Back grey_arrow_rt.gif
 
 
 
SUSTAINED VIROLOGIC RESPONSE RATES AND VIRAL RESISTANCE PROFILES WERE SIMILAR IN PATIENTS TREATED WITH A TELAPREVIR-BASED REGIMEN REGARDLESS OF LIVER FIBROSIS STAGE
 
 
  Reported by Jules Levin
22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), Taipei, Taiwan, February 16-19, 2012
 
Patrick Marcellin1, James C Sullivan2, Michael W Fried3, Tara L Kieffer2, Geoffrey M Dusheiko4, Emily C Martin2, David R Nelson5, Adrian M Di Bisceglie6, Gregory T Everson7, Nathalie Adda2 1University of Paris Clichy, Clichy, France; 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 4Royal Free and University College, London, United Kingdom; 5University of Florida, Gainesville, FL, USA; 6Saint Louis University School of Medicine, Saint Louis, MO, USA; 7University of Colorado, Denver, CO, USA

APSL1.gif

APSL2.gif

APSL3.gif

APSL4.gif

APSL5.gif